Abstract
We review here some recent data about Glucose-6-phosphate dehydrogenase (G6PD), the housekeeping X-linked gene encoding the first enzyme of the pentose phosphate pathway (PPP), a NADPH-producing dehydrogenase.
This enzyme has been popular among clinicians, biochemists, geneticists and molecular biologists because it is the most common form of red blood cell enzymopathy. G6PD deficient erythrocytes do not generate NADPH in any other way than through the PPP and for this reason they are more susceptible than any other cells to oxidative damage. Moreover, this enzyme has also been of crucial importance in many significant discoveries; indeed, G6PD polymorphisms have been instrumental in studying X-inactivation in the human species, as well as in establishing the clonal nature of certain tumors.
G6PD deficiency, generally considered as a mild and benign condition, is significantly disadvantageous in certain environmental conditions like in presence of certain drugs. Nevertheless, G6PD deficiency has been positively selected by malaria, and recent knowledge seems to show that it also confers an advantage against the development of cancer, reduces the risk of coronary diseases and has a beneficial effect in terms of longevity.
Keywords: Cancer, cardiovascular diseases, development, G6PD deficiency, longevity, malaria, oxidative stress, stem cell differentiation.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Glucose-6-Phosphate Dehydrogenase Deficiency: Disadvantages and Possible Benefits
Volume: 13 Issue: 1
Author(s): Genesia Manganelli, Ugo Masullo, Stefania Passarelli and Stefania Filosa
Affiliation:
Keywords: Cancer, cardiovascular diseases, development, G6PD deficiency, longevity, malaria, oxidative stress, stem cell differentiation.
Abstract: We review here some recent data about Glucose-6-phosphate dehydrogenase (G6PD), the housekeeping X-linked gene encoding the first enzyme of the pentose phosphate pathway (PPP), a NADPH-producing dehydrogenase.
This enzyme has been popular among clinicians, biochemists, geneticists and molecular biologists because it is the most common form of red blood cell enzymopathy. G6PD deficient erythrocytes do not generate NADPH in any other way than through the PPP and for this reason they are more susceptible than any other cells to oxidative damage. Moreover, this enzyme has also been of crucial importance in many significant discoveries; indeed, G6PD polymorphisms have been instrumental in studying X-inactivation in the human species, as well as in establishing the clonal nature of certain tumors.
G6PD deficiency, generally considered as a mild and benign condition, is significantly disadvantageous in certain environmental conditions like in presence of certain drugs. Nevertheless, G6PD deficiency has been positively selected by malaria, and recent knowledge seems to show that it also confers an advantage against the development of cancer, reduces the risk of coronary diseases and has a beneficial effect in terms of longevity.
Export Options
About this article
Cite this article as:
Manganelli Genesia, Masullo Ugo, Passarelli Stefania and Filosa Stefania, Glucose-6-Phosphate Dehydrogenase Deficiency: Disadvantages and Possible Benefits, Cardiovascular & Hematological Disorders-Drug Targets 2013; 13 (1) . https://dx.doi.org/10.2174/1871529X11313010008
DOI https://dx.doi.org/10.2174/1871529X11313010008 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Understanding the Cardiovascular Actions of Soy Isoflavones: Potential Novel Targets for Antihypertensive Drug Development
Cardiovascular & Hematological Disorders-Drug Targets Implications of Nanotechnology in Healthcare
Nanoscience & Nanotechnology-Asia Plasma Level of D-dimer is an Independent Diagnostic Biomarker for Deep Venous Thrombosis in Patients with Ischemic Stroke
Current Neurovascular Research The Future of Angiotensin II Inhibition in Cardiovascular Medicine
Current Drug Targets - Cardiovascular & Hematological Disorders Endothelin and the Ischaemic Heart
Current Vascular Pharmacology Microbial Biotransformation: Recent Developments on Steroid Drugs
Recent Patents on Biotechnology Adrenergic and V1-ergic Agonists/Antagonists Affecting Recovery from Brain Trauma in the Lund Project Act on Astrocytes
Current Signal Transduction Therapy Progress of Biological Agents on Psoriatic Arthritis
Current Pharmaceutical Biotechnology Genetics and Heart Failure: A Concise Guide for the Clinician
Current Cardiology Reviews IL-6 Signaling and its Blockade with a Humanized Anti-Interleukin-6 Receptor Antibody in Rheumatoid Arthritis: Advent of a New and Innovative Therapeutic Drug, Tocilizumab
Current Rheumatology Reviews Inflammation in Atherosclerosis: A New Therapeutic Target
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Effects of Huangkui Capsule on the Expression of SPARC in the Kidney Tissue of a Rat Model with Diabetic Nephropathy
Current Gene Therapy Do Advanced Glycation End Products (AGEs) Contribute to the Comorbidities of Polycystic Ovary Syndrome (PCOS)?
Current Pharmaceutical Design Combination of Phytosterols and Omega-3 Fatty Acids: A Potential Strategy to Promote Cardiovascular Health
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Targeting Monoamine Oxidases with Multipotent Ligands: An Emerging Strategy in the Search of New Drugs Against Neurodegenerative Diseases
Current Medicinal Chemistry CYP3A4 *1B Gene Polymorphism in Coronary Artery Disease Patients with Obesity Undergoing Statin Treatment
Current Pharmacogenomics and Personalized Medicine Nutrigenomics and its Impact on Life Style Associated Metabolic Diseases
Current Genomics Decrease in Secondary Neck Vessels in Multiple Sclerosis: A 5-year Longitudinal Magnetic Resonance Angiography Study
Current Neurovascular Research Cinnamic Acid Derivatives in Tuberculosis, Malaria and Cardiovascular Diseases - A Review
Current Organic Chemistry Smoking and Atherosclerosis: Mechanisms of Disease and New Therapeutic Approaches
Current Medicinal Chemistry